NKGen Biotech Inc. and Graf Acquisition IV Announce Nominees for Independent Board Members
NKGen Biotech Inc. (NKGen) and Graf Acquisition IV (NYSE:GFOR) have announced the nomination of Michael Klowden and Kathleen Scott as independent members of the Board of Directors for the post-business combination company, New NKGen.
Assuming the director nominees are elected by the stockholders of Graf at the special meeting to approve the business combination, their appointment will be effective upon the closing of the business combination, expected to occur in the third quarter of 2023.
Michael Klowden, currently serving as the executive vice chairman of the board of the Milken Institute, brings over 21 years of experience as the institute’s chief executive officer. During his tenure, the institute’s reputation and worldwide outreach were enhanced, and multiple specialized centers were created. Prior to this, Mr. Klowden worked as president of Jefferies Group Inc, a global investment bank and institutional securities firm, and as a senior partner at the international law firm Morgan, Lewis & Bockius LLP. He holds a bachelor’s degree from the University of Chicago and a J.D. From Harvard Law School.
Kathleen Scott, the current chief financial officer of ARS Pharmaceuticals, Inc. has extensive financial expertise and experience in the life science industry. She has also served as the chief financial officer of various other life science companies and is a member of the boards of directors of Dermata Therapeutics, Inc. the YMCA of San Diego County, and Corporate Directors Forum. Ms. Scott started her career as an auditor at Arthur Andersen’s San Diego office and holds a bachelor’s degree in economics and business from the University of California, Los Angeles.
In a statement, Paul Y. Song, M.D., CEO of NKGen, expressed his excitement and honor in nominating Michael and Kathleen to New NKGen’s Board. He believes that their extensive experience and expertise will bring valuable insights and perspectives to the company as it continues to advance its innovative NK cell therapies and drive growth.
NKGen Biotech Inc and Graf Acquisition IV have announced the nomination of Michael Klowden and Kathleen Scott as independent members of the Board of Directors for the post-business combination company, New NKGen.
